Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 15, 2012 02:30 ET | Source: Active Biotech

Active Biotechs valberedning utsedd

Enligt beslut från årsstämman den 10 maj 2012, skall valberedningen för Active Biotech bestå av representanter för de, i slutet av september månad 2012, tre största ägarna, samt styrelsens...
November 15, 2012 02:30 ET | Source: Active Biotech

Active Biotech's election committee appointed

In accordance with a decision made by the Annual General Meeting held on May 10, 2012, the Election Committee shall comprise the representatives for the three largest shareholders, as per end of...
November 09, 2012 02:30 ET | Source: Active Biotech

Active Biotech AB Delårsrapport januari - september 2012

· Laquinimod - Teva inleder ny fas III-studie vid årsskiftet - delmålsbetalning om 5 MUSD erhållen efter inlämnad registreringsansökan i Europa - Fas II-data...
November 09, 2012 02:30 ET | Source: Active Biotech

Active Biotech AB Interim report January - September 2012

· Laquinimod - Teva to initiate a new Phase III study in the US at year-end - milestone payment of USD 5 M received following a submitted application for regulatory approval in...
October 22, 2012 09:00 ET | Source: Active Biotech

POSITIVA FAS IIa-DATA FÖR LAQUINIMOD FÖR BEHANDLING AV AKTIV CROHNS SJUKDOM

Nya data från konferensen "20th United European Gastroenterology (UEG) Week" visar att laquinimod signifikant minskar de kliniska symptomen jämfört med placebo Lund, Sverige och Jerusalem, Israel...
October 22, 2012 09:00 ET | Source: Active Biotech

PHASE IIa LAQUINIMOD TRIAL RESULTS SHOW POSITIVE DATA FOR POTENTIAL USE IN ACTIVE CROHN'S DISEASE

Newly Presented Data at 20th United European Gastroenterology (UEG) Week Conference Show Significant Impact of Laquinimod on Clinical Remission versus Placebo Jerusalem, Israel and Lund, Sweden,...
October 19, 2012 01:15 ET | Source: Active Biotech

Active Biotechs samarbetspartner Ipsen inleder en "proof of concept"-studie med tasquinimod i ytterligare cancerindikationer

Lund den 19 oktober, 2012 - Active Biotech (NASDAQ OMX NORDIC: ACTI) meddelar idag att samarbetspartnern Ipsen (Euronext: IPN; ADR: IPSEY, läs pressmeddelandet här) kommer att inleda en ny fas...
October 19, 2012 01:15 ET | Source: Active Biotech

Active Biotech's partner Ipsen initiates a proof-of-concept study with tasquinimod in additional cancer indications

Lund, Sweden, October 19, 2012 - Active Biotech (NASDAQ OMX NORDIC: ACTI) today announces that its partner Ipsen (Euronext: IPN; ADR: IPSEY, read press release here) will initiate a new phase II,...
October 03, 2012 12:30 ET | Source: Active Biotech

Ipsen inleder en underhållsterapi fas II-studie med tasquinimod i kastratresistent metastaserad prostatacancer

Lund (Sverige) och Paris (Frankrike) den 3 oktober, 2012 - Active Biotech (NASDAQ OMX NORDIC: ACTI) och Ipsen (Euronext: IPN; ADR: IPSEY) meddelar idag att en ny fas II "proof of concept" klinisk...
October 03, 2012 12:30 ET | Source: Active Biotech

Ipsen initiates a phase II "Switch maintenance" trial in metastatic castrate-resistant prostate cancer with tasquinimod

Paris (France) and Lund (Sweden), 3 October 2012 - Ipsen (Euronext: IPN; ADR: IPSEY) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced the initiation of a new phase II proof of concept...